Clinical Trial Update: Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in patients with stage IB-IV mycosis fungoides and Sezary syndrome has completed, with results posted on August 11, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Mycosis Fungoides, Sezary Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-08-11